Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEM-CESAR: KRd + ASCT in High-Risk Smoldering Multiple Myeloma
NCT02415413Phase 2Active, not recruiting
- Sponsor
- Fundación PETHEMA
- Start
- May 2015
- Primary completion
- Jul 2018
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in smoldering multiple myeloma (SMM), sponsored by Fundación PETHEMA. Started May 2015; status: active, not recruiting.
02
Drugs
carfilzomib
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT02415413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02415413.